Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy

BACKGROUND: Anti-GD2 monoclonal antibody immunotherapy has significantly improved the overall survival rate for high-risk neuroblastoma patients. However, 40% of patients fail to respond or develop resistance to treatment, and the molecular mechanisms by which this occurs remain poorly understood. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoming, Wills, Carson A, Chen, Longgui, Zhang, Jiawen, Zhao, Yuanjun, Zhou, Mi, Sundstrom, Jeffrey M, Schell, Todd, Spiegelman, Vladimir S, Young, Megan M, Wang, Hong-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052051/
https://www.ncbi.nlm.nih.gov/pubmed/35483745
http://dx.doi.org/10.1136/jitc-2021-004399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052051/
https://www.ncbi.nlm.nih.gov/pubmed/35483745
http://dx.doi.org/10.1136/jitc-2021-004399

Ejemplares similares